The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s Category 1 drug, keverprazan, for the treatment of duodenal ulcers and reflux esophagitis in China. This approval marks a significant advancement in the treatment options available for these gastrointestinal conditions.
Keverprazan: A New Potassium Competitive Acid Blocker (PCAB)
Keverprazan is a novel potassium competitive acid blocker (PCAB) that inhibits gastric acid secretion by binding to the K+ binding site on H+-K+-ATPase. This mechanism of action makes it an effective treatment for conditions such as duodenal ulcers and reflux esophagitis, where reducing gastric acid secretion is crucial for symptom relief and healing.
Market Precedents and NRDL Inclusion
Similar products in the PCAB class, such as Takeda’s vonoprazan and Luoxin Pharma’s tegoprazan, have already been approved in China and have been included in the National Reimbursement Drug List (NRDL). The approval of keverprazan further expands the range of treatment options available to patients and healthcare providers, potentially improving access to effective therapies for these common conditions.-Fineline Info & Tech
